173 related articles for article (PubMed ID: 32132528)
1. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy.
Zhang W; Xu L; Park HB; Hwang J; Kwak M; Lee PCW; Liang G; Zhang X; Xu J; Jin JO
Nat Commun; 2020 Mar; 11(1):1187. PubMed ID: 32132528
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
4. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
5. Identification of FimH derivatives as adjuvant vaccinated with PAc that enhance protection against Streptcoccus mutans colonization.
Liu Z; Chen J; Li W; Bi Y; Li Y; Fan M
Mol Cell Probes; 2019 Jun; 45():19-25. PubMed ID: 30940544
[TBL] [Abstract][Full Text] [Related]
6. FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice.
Abdul-Careem MF; Firoz Mian M; Gillgrass AE; Chenoweth MJ; Barra NG; Chan T; Al-Garawi AA; Chew MV; Yue G; van Roojen N; Xing Z; Ashkar AA
Antiviral Res; 2011 Nov; 92(2):346-55. PubMed ID: 21945041
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
8. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.
Ashkar AA; Mossman KL; Coombes BK; Gyles CL; Mackenzie R
PLoS Pathog; 2008 Dec; 4(12):e1000233. PubMed ID: 19057665
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
11. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
12.
Zhang W; Xu L; Zhang X; Xu J; Jin JO
Front Immunol; 2023; 14():1213467. PubMed ID: 37720226
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand.
Mossman KL; Mian MF; Lauzon NM; Gyles CL; Lichty B; Mackenzie R; Gill N; Ashkar AA
J Immunol; 2008 Nov; 181(10):6702-6. PubMed ID: 18981086
[TBL] [Abstract][Full Text] [Related]
14. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
15. A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
Seya T; Takeda Y; Matsumoto M
Adv Drug Deliv Rev; 2019 Jul; 147():37-43. PubMed ID: 31302192
[TBL] [Abstract][Full Text] [Related]
16. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
18. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
19. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.
Brunner C; Seiderer J; Schlamp A; Bidlingmaier M; Eigler A; Haimerl W; Lehr HA; Krieg AM; Hartmann G; Endres S
J Immunol; 2000 Dec; 165(11):6278-86. PubMed ID: 11086063
[TBL] [Abstract][Full Text] [Related]
20. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
